Cephalon to pay $425M for improper drug marketing

PHILADELPHIA (AP) -- Drug maker Cephalon has completed a previously announced $425 million civil settlement with federal authorities over off-label drug marketing.

Federal authorities in Philadelphia say Cephalon Inc. marketed three drugs for uses other than what they were federally approved for. Cephalon disclosed the tentative settlement last November.

Authorities say Cephalon marketed one of the drugs, Actiq, for maladies including migraines and injuries. But authorities say the fentanyl lollipop is a highly addictive narcotic approved only for certain cancer patients.

The suburban Philadelphia company has signed an agreement to plead guilty to one count of distribution of misbranded drugs.

(Copyright 2008 by The Associated Press. All Rights Reserved.)

You must be logged in to post comments.

Password (case sensitive):
Remember Me:


6450 Papermill Drive Knoxville, TN 37919 Phone - (865) 450-8888; Fax - (865) 450-8869
Copyright © 2016 WVLT-TV Inc. - Designed by Gray Digital Media - Powered by Clickability 29889354 - local8now.com/a?a=29889354
Gray Television, Inc.